NEW MEDICINE PARTNERS

We are an advisory company that creates strategies for precision medicine health to advance healthy lifespan, utilising power of AI to target and personalise. We work with government agencies, investors, public and private health service providers, SMEs, start-ups, and research organisations.

Services Enquiries

Healthspan / Longevity Clinic Advisory Services

We advise newly established clinics on product / client strategy, regulatory requirements, equipment, capacity and operational planning and utilisation management, and provide tailored support to existing aesthetic clinics wishing to expand into healthy longevity-focused establishments.

Services Enquiries

Longevity Technology Transfer and Commercialisation

We advise technology developers on market positioning, business case, value behind a longevity or preventative health technology and facilitate strategic partnerships for development and exit. We help technology adopters - investors and businesses - to discover early-stage longevity products with long-term market potential.

Services Enquiries

HEALTH SYSTEM OPTIMISATION FOR HEALTHY LONGEVITY

We advise on adaptation of national, provider and payor strategies for healthy longevity and care pathways. We specialise in personalised healthspan programmes, using AI tools for population analysis for early intervention and clinical decision making, and strategies for engagement of patients and clinicians.

Services Enquiries

Healthy longevity

Healthy longevity, or healthspan, is the one goal that unites all of humanity. Living longer is desirable only if the years gained are spent in good health. Who would not want to stay healthy for as long as possible? We now have the insight and technology to make it a reality. Preventative healthcare can bring in healthy longevity for all if we invest in precision population health, democratise access to health services and digital tools, and use emerging technology efficiently.

The rapidly growing longevity market offers financial rewards - increasing spending on preventative healthcare by 0.1% can unlock 9% increase in economic contribution. By preventing or postponing chronic disease and promoting healthy ageing we can all reap the benefits of living longer and happier lives.

We focus Healthy longevity, or healthspan
$26 bn
Size of the global longevity
market (2023)
$27 tn
The value to society of 1 year increase in healthspan (2023)
Our Purpose
We work with leading organisations to advance the state of disease prevention and the products of longevity science and their translation into practical application.
Our Mission
To bring the most promising preventative health technologies to the market and maximise their impact to the society and the individual.
Our Values
Imagination, ambition and expertise - applied responsibly. Healthspan is more important than lifespan. Prevention is better than cure.

Why US?

We are a highly experienced team with a wide ranging expertise from national policy and strategy to technology transfer and technology assessment to AI development and implementation for predictive healthcare. Our industry experience, technical knowledge and relationships within the healthcare sector brings value to organisations at every phase of their technology development. We facilitated market entry of innovative technologies in the UK, EU, North America, and Asia Pacific. We do not outsource any of our work and do not employ junior analysts; if you work with us you will get expert knowledge, disruptive thinking and tailored engagement to the needs of your project.

Services Our Team

Past Projects

The Royal Society of Medicine

The Royal Society of Medicine: New Medicine Partners will support the development of an innovation strategy for the Royal Society of Medicine. A key goal is to enable the NHS to benefit from the onrush of AI and digital innovation, adding value to innovators in digital health, medical devices and biopharmaceuticals. The RSM is in a unique position to tackle one of the most persistent challenges in UK healthcare.

Kemijski Institut, National Institute of Chemistry (NIC)
Slovenia

New Medicine Partners is providing advisory services to Kemijski Institut, Slovenia. NMP will assist Kemijski Institut in development and internationalisation of their novel cell and gene therapies.

Kent Surrey Sussex Academic Health Science Network

New Medicine Partners is providing advisory services to Kent Surrey Sussex Academic Health Science Network. NMP will assist KSS AHSN in developing a commercial model for the Accelerated Medicines Digital Design Studio as a part of the bid for consortium funding.

Naturalworks

NMP is assisting this UK-based startup company in assessing the potential of CBD oil in health, wellness and longevity applications with the focus on cancer and arthritis.

Veratrak

NMP is assisting this UK-based startup company in using its technology to revolutionise pharmaceutical supply chains including COVID-19 and cell and gene therapies.

Past Projects

Linkedin Feed

New Medicine Partners
💪 ProFuse is taking on muscle loss — one cell at a time. The Israeli biotech startup has launched a new drug discovery platform that uses its mature, lab-grown human muscle tissue to screen compounds that may prevent or reverse muscle wasting from aging, cancer, and even GLP-1 weight-loss drugs. Why it matters: 🧓 Sarcopenia affects up to 50% of people over 80 🏋️ GLP-1s like Ozempic are reshaping metabolic health – but can cause muscle loss 🧬 ProFuse’s 3D-cultivated muscle tech offers a powerful new model for screening and discovery Key highlights: - Built on tech from the Weizmann Institute of Science - Accelerates muscle progenitor ce...
Go to post
New Medicine Partners
🧬 Could proximity be the master switch of biology? General Proximity thinks so — and they’re pioneering a new class of small molecule drugs that work by hijacking cellular “proximity events” to do what most therapeutics can’t: modulate the so-called undruggable. From refolding or activating proteins to cellular reprogramming, their proximity platform is unlocking therapeutic transformations once thought impossible — all using drugs that are scalable, affordable, and orally available. 🔑 What’s the science? - Biological function is often governed by proximity — molecules coming together to trigger effects (e.g., rapamycin’s FKBP12-mTOR...
Go to post
New Medicine Partners
🧬 Weekly Rapamycin Shows Promise in Women’s Healthspan – PEARL Trial Findings Are In Can an old immunosuppressant become a longevity therapy? The PEARL trial – the first long-term, placebo-controlled clinical study on low-dose weekly rapamycin in healthy adults – just released results. And while it didn’t hit its primary endpoint (reducing visceral fat), one group saw a notable benefit: women taking 10 mg/week had a statistically significant increase in lean muscle mass. 🧪 Key takeaways: • 114 participants, aged 50–85, randomized into placebo, 5 mg/week, and 10 mg/week groups • Primary outcome (visceral adiposity) ⛔ not met ...
Go to post
New Medicine Partners
🧠 From Nose to Neurons: Subsense Is Building a Nanotech BCI That Could Replace Brain Implants Forget surgery – what if your brain-computer interface could be delivered through your nose? Subsense, a next-gen neurotech company, just emerged from stealth with a $17M seed round and a bold vision: to build a non-surgical BCI that’s as precise as implanted devices — but powered by nanoparticles instead of wires. 💡 The tech: Plasmonic nanoparticles for neural reading (via light signals) Magnetoelectric nanoparticles for stimulation (via magnetic fields) Delivered non-invasively through the olfactory nerve or bloodstream Their early focus? Treating ...
Go to post
New Medicine Partners
🧠 Big Move in Brain Health Tech: MYndspan & EMOTIV Partner to Bring Clinical-Grade Brain Monitoring to Everyone Brain health is stepping into a new era. Today, MYndspan, the company bringing MEG brain scans to consumers, announced a strategic partnership (and investment!) from EMOTIV, the leading wearable EEG company. Together, they plan to fuse MEG’s high-resolution brain imaging with EMOTIV’s real-time, everyday neurotracking — making proactive brain health monitoring scalable and personalized. Why it matters: 🧬 MYndspan’s MEG-based assessments (like Functional Brain Age and Brain Stability Index) can flag early signs of neurodegeneration...
Go to post
New Medicine Partners
🧬 New Discovery in Mitochondrial Regulation May Unlock Therapies for Aging Diseases Researchers have uncovered a mitochondrial membrane protein, TMEM65, that could hold the key to tackling a core driver of aging: calcium overload in cells. In a new study published in Nature Metabolism, scientists at Temple University revealed that TMEM65 plays a crucial role in regulating NCLX — the primary mitochondrial sodium-calcium exchanger. Why does this matter? Because mitochondrial calcium overload leads to cellular dysfunction and is implicated in diseases like heart failure, Alzheimer’s, and sarcopenia. 💡 Key takeaways: - TMEM65 acts as a gatekeeper for m...
Go to post
New Medicine Partners
🧬 Rewinding the Cellular Clock: New iPSC Banking Service Launches in the US Imagine storing a bank of your own rejuvenated stem cells — age-reversed and ready for future therapies. That future just got a little closer. Japanese biotech I Peace has officially launched its personalized induced pluripotent stem cell (iPSC) production and banking service, "My Peace," in the United States. Announced last week at the Vitalist Bay longevity summit, the offering enables individuals to produce and store their own youthful stem cells while they’re still healthy, creating a personalized cellular reserve for future regenerative and longevity applications. 🔁 ...
Go to post
New Medicine Partners
🧬 The “Longevity Nutrient” You’ve Probably Never Heard Of: C15:0 Could a little-known fatty acid be the missing piece in our fight against aging? Veterinary scientist–turned–longevity trailblazer Dr. Stephanie Venn-Watson thinks so. Her new book, The Longevity Nutrient, explores how an overlooked saturated fat—C15:0 (pentadecanoic acid)—may play a foundational role in slowing biological aging, improving metabolic health, and boosting cellular resilience. 🔍 Discovered through dolphin research (yes, really), C15:0 is found in trace amounts in full-fat dairy and certain fish. As low-fat diets have become the norm, C15:0 intake has decline...
Go to post
New Medicine Partners
🧬 Can Gene Silencing Reset Aging Cells? A new wave of longevity biotech is emerging — and Junevity is leading the charge with a promising approach to cellular rejuvenation using gene-silencing therapeutics. Rather than reprogramming cells into stem cells (à la Yamanaka factors), Junevity is targeting transcription factors that go haywire in aging and disease. Their tool of choice? siRNA (small interfering RNA) — a maturing technology now capable of safely and precisely silencing genes that drive cellular dysfunction. 🔬 How it works: ✅Using machine learning and massive patient datasets, Junevity identifies transcription factors that regulate ...
Go to post



“Richard Barker has been instrumental in guiding our early stage business through critical phases of growth. His deep expertise and strategic insights into the Life Sciences Industry have proven invaluable. Richard not only provided us with a comprehensive understanding of market trends and dynamics but also offered actionable advice on refining our product offering to better meet industry demands. We are grateful for Richard's unwavering support, guidance, and invaluable contributions to our journey. His dedication to empowering early stage businesses in the Life Sciences sector makes him not just a consultant but a true partner in our success.”

Jason Lacombe, CEO of Veratrak





“I worked with Olga Shvarova on a project, which exemplified the transformative potential of combining digital technology with life sciences and reducing barriers for innovation. From day one, Olga demonstrated a deep understanding of the intricate challenges of the project and quickly unraveled the complexities of the project and delivered a commercial strategy that brought clarity to our vision. She brought clarity and rigor to an incredibly complex project and her ability to transform visionary ideas into a structured, actionable commercial model set the foundation for everything we’ve achieved since. Olga didn’t just help us plan for success - she prepared us to thrive in the long term."

Melissa Ream, AI Adviser of Kent Surrey Sussex Academic Health Science Network (KSS AHSN),
now known as Health Innovation KSS





“Olga Shvarova helped us to understand the market potential, regulatory pathways, and to identify the value proposition that formed the foundation of our commercial strategy. She facilitated the introductions that led to academic partnerships for the development of our novel
micelle solution, which significantly accelerated our technology development efforts.
We are grateful for the support we received at the early stage before the larger in-house team was assembled as well as the feedback and strategic recommendation on IPR protection and in-licensing options which helped us to make informed decisions early on.”

Filipp Korentsvit, CEO of NaturalWorks, now NWPharma Ltd



Partner Organisations